HC Wainwright Reaffirms "Neutral" Rating for Chimerix (NASDAQ:CMRX)

Chimerix (NASDAQ:CMRX - Get Free Report)'s stock had its "neutral" rating reissued by equities researchers at HC Wainwright in a research note issued on Wednesday, MarketBeat Ratings reports. They presently have a $8.55 target price on the biopharmaceutical company's stock, down from their previous target price of $11.00. HC Wainwright's price objective indicates a potential upside of 1.42% from the company's previous close.

Separately, Wedbush restated an "outperform" rating and issued a $7.00 price target (up previously from $6.00) on shares of Chimerix in a research report on Tuesday, February 18th.

Chimerix Stock Performance

Shares of NASDAQ:CMRX remained flat at $8.43 during mid-day trading on Wednesday. 7,018,814 shares of the company traded hands, compared to its average volume of 2,037,837. The stock has a market capitalization of $758.16 million, a P/E ratio of -8.97 and a beta of 0.32. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $8.47. The firm's 50-day simple moving average is $4.34 and its 200 day simple moving average is $2.32.

Insider Activity at Chimerix

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the sale, the chief executive officer now owns 609,603 shares in the company, valued at $2,755,405.56. This represents a 1.19 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 20,760 shares of company stock worth $91,175. 13.10% of the stock is owned by corporate insiders.

Remove Ads

Institutional Investors Weigh In On Chimerix

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bender Robert & Associates purchased a new stake in Chimerix in the 4th quarter worth approximately $37,000. Susquehanna Fundamental Investments LLC purchased a new stake in Chimerix in the 4th quarter worth approximately $59,000. Jane Street Group LLC purchased a new stake in Chimerix in the 4th quarter worth approximately $62,000. Diadema Partners LP acquired a new position in shares of Chimerix during the 4th quarter worth $101,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Chimerix during the 4th quarter worth $130,000. Hedge funds and other institutional investors own 45.42% of the company's stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.